四川正加速推进集采药品下沉基层，不久的将来老百姓就不用为买集采药品专门去大医院，在家门口的 药店、民营医院或村卫生室就能买到。2025年12月30日，四川省医保局发出相关通知，将采取措施进一 步促进集采药品进基层医疗机构、进民营医疗机构、进零售药店（以下简称"三进"）。 "集采药品'三 进'，旨在进一步扩大集采政策覆盖面，让人民群众能在更多渠道、就近就便享受到集采改革成果。"省 医保局相关负责人表示，四川将进一步扩大集采覆盖范围，公立基层医疗机构，包括乡镇卫生院、社区 卫生服务中心/站、村卫生室等，按政策规定参加集采。鼓励并引导定点民营医疗机构、定点零售药店 参加集采，并配备一定数量集采药品。（四川日报） ...

孙文丽 德州报道 12月30日,德城区政府新闻办举行德城"十四五"发展成就系列主题新闻发布会第九场,德城区医疗保障局 党组成员杜志恒就药品和医用耗材集中采购的相关措施答记者问。 强化全流程管理,提升惠民实效。依托省药品和医用耗材招采管理平台,加强精准报量、协议签订、供应 保障、采购执行等集采全流程各环节的动态监测和跟踪服务。同时,压实医疗机构采购责任,加强集采业 务专题培训,确保按时完成集采约定量。截至目前,全区已有16家定点医院规范参与集采,执行效率与数据 质量稳步提升。已累计落地执行集采药品20批次共890种,集采耗材22批次共43类,众多质优价廉的集采药 品和医用耗材在我区得以应用。 优化结算机制,缩短药企回款周期。压实医疗机构向医保部门及时回款责任,货款按时由医保部门统一与 医药企业进行结算,保障药品和医用耗材"快采快结",显著压缩了企业回款周期,降低交易成本,提升资金周 转效率。截至目前,已累计实现医保直接结算药品货款23337万元、医用耗材货款3283万元,有力保障了医 药企业权益和集采机制顺利运行。 完善激励机制,激发医疗机构动力。严格落实药品和医用耗材集中采购医保资金结余留用激励政策,将节 约 ...

（来源：衢州日报） 转自：衢州日报 "这下购房压力小多了。"日前，刚办理好公积金贷款业务的杨先生说。作为此次公积金新政惠及的青年 人，他申请到136万元贷款，恰好补上付完首付后的其余房款。 "得益于我市新出台的公积金贷款额度上浮政策，像杨先生这样的年轻人，家庭最高可贷额度由原来的 130万元提升至169万元。"金华市住房公积金管理中心工作人员介绍，该政策自今年12月1日起施行，明 确申请办理住房公积金相关业务时获得金华市户籍未满3年或非金华市户籍的新市民以及年龄在40周岁 （含）以内的青年人，租房可按实际房租支出提取住房公积金；购买自住住房申请住房公积金贷款的， 贷款额度可上浮30%。 这一政策调整不仅为青年购房群体带来优惠，还推出"允许提取父母、子女公积金还贷"的条款。"一家 人互相支持，心里踏实多了。"看到新政策后，吴先生就立即和父母商量，并于12月5日申请办理按年支 取还贷代际提取公积金业务，母亲任女士为其还贷8万余元。 此外，绿色建筑、多孩家庭贷款额度上浮等举措，打消了大量缴存人的购房资金顾虑，为刚性和改善性 住房需求提供有力支撑，帮助更多缴存人实现安居梦想。据《金华日报》 抚州： 集采药品"三进"便 ...

Group 1 - The Central Economic Work Conference highlighted the importance of maintaining confidence in development and outlined key tasks for economic and social development in the coming year [1][2] - The conference emphasized the need to focus on high-quality development and proposed eight key tasks for the upcoming economic work, with a strong emphasis on domestic demand and consumption [7][10] - The meeting underscored the significance of innovation and the role of emerging industries, particularly in technology and agriculture, to drive economic growth [8][9] Group 2 - The conference reported that the agricultural sector has seen significant financial support, with county-level loans exceeding 11 trillion yuan, indicating a strong commitment to rural revitalization [9] - Investment in water conservancy projects in Guangdong is expected to reach 109 billion yuan, marking a record high, which is crucial for stabilizing economic growth [5] - The meeting called for enhancing macroeconomic governance and implementing proactive fiscal policies to ensure economic stability and growth [10][11]

Core Insights - 2025 is a pivotal year for China's pharmaceutical sector, marked by the implementation of policies aimed at enhancing service quality and accessibility, as well as the transition from the "14th Five-Year Plan" to the "15th Five-Year Plan" [1][2] Group 1: Healthcare System Improvements - Over 90% of township health centers and community health service centers have met basic service capability standards, with many reaching recommended standards [1] - The inclusion of the HPV vaccine in the national immunization program enhances public health protection [1][5] - The proportion of diagnoses from grassroots medical institutions has remained above 50% since the "14th Five-Year Plan" began, indicating a significant role in healthcare delivery [4] Group 2: Medical Insurance and Procurement Reforms - The 11th batch of national drug procurement included 55 drugs across various therapeutic areas, with a focus on maintaining clinical stability and quality [6][9] - The national medical insurance bureau is advancing direct settlements with pharmaceutical companies and optimizing procurement measures to ensure quality and supply [7][9] - The introduction of a commercial insurance directory for innovative drugs marks a significant step in expanding healthcare coverage [11][12] Group 3: Support for Pharmaceutical Innovation - The government has introduced measures to support the development of innovative drugs, including financial backing and streamlined approval processes [10][11] - Approximately 80% of innovative drugs are expected to be included in the medical insurance directory within two years of their market launch [11] - The launch of the drug price registration system aims to facilitate a global pricing strategy for pharmaceutical companies, enhancing their market competitiveness [12]

Group 1: US-China Trade Relations - The meeting between Chinese President Xi Jinping and US President Donald Trump in Busan resulted in a consensus on key trade issues, aiming to enhance cooperation in economic and trade fields [1][2] - The US agreed to cancel the 10% "fentanyl tariff" on Chinese goods and to continue the suspension of a 24% tariff for one year, while China will adjust its countermeasures accordingly [1] - Both sides reached agreements on various topics, including maritime, logistics, and shipbuilding industry measures, as well as agricultural trade and export controls [1] Group 2: China's 14th Five-Year Plan - The "14th Five-Year Plan" emphasizes maintaining economic growth within a reasonable range without setting explicit growth targets, focusing instead on high-quality development [3][4] - Key goals include significantly increasing the resident consumption rate and enhancing the role of domestic demand in driving economic growth [3] - The plan outlines the need for proactive fiscal policies and the construction of a robust financial system to support sustainable economic development [3] Group 3: Federal Reserve Interest Rate Decision - The Federal Reserve lowered the federal funds rate target range by 25 basis points to between 3.75% and 4.00%, marking the fifth rate cut since September 2024 [5][6] - Economic indicators show moderate expansion, with employment growth slowing and inflation remaining high, leading to a cautious approach regarding future rate cuts [5][6] - Fed Chairman Jerome Powell indicated uncertainty about further rate cuts in December, citing ongoing economic pressures from government shutdowns [6] Group 4: Shanghai Composite Index - The Shanghai Composite Index surpassed the 4000-point mark for the first time in ten years, closing at 4016.33 points, reflecting improved market sentiment and investor confidence [7] - The index's rise from 3000 to 4000 points took 13 months, contrasting sharply with previous rapid increases in 2007 and 2015 [7] - Analysts suggest that ongoing progress in US-China trade negotiations and supportive regulatory policies may contribute to a stable upward trend in the A-share market [7] Group 5: Industrial Profit Growth - In September, industrial profits for large-scale enterprises increased by 21.6% year-on-year, with cumulative profits for the first nine months rising by 3.2% [10][11] - The high-tech manufacturing sector showed significant growth, with profits increasing by 8.7% year-on-year, contributing to overall industrial profit growth [11] - The broadening profit growth across various industries indicates a recovery trend, supported by domestic demand and policy measures [11] Group 6: Drug Procurement Expansion - The latest round of national drug procurement successfully included 55 drugs, expanding the total to 490, with a focus on commonly used medications [12] - The competitive nature of the procurement process was highlighted, with over 450 products participating and a high selection rate due to the introduction of a revival mechanism [12] - The procurement aims to stabilize clinical supply, ensure quality, and prevent extreme pricing behaviors, reflecting an optimization of the procurement process [12] Group 7: Nvidia's Market Milestone - Nvidia's market capitalization reached $5.13 trillion, making it the first company to surpass the $5 trillion mark, driven by strong demand for AI technology [13] - CEO Jensen Huang projected significant revenue growth from upcoming chip architectures, indicating a robust future for the company [13] - Nvidia's investment in Nokia aims to accelerate innovations in AI and 5G technologies, further solidifying its position in the tech industry [13]

Core Points - The 11th batch of national organized drug procurement successfully opened bidding on October 27 in Shanghai, with 55 drugs successfully procured. Over the past seven years, 490 high-quality and affordable essential and life-saving drugs have entered the public's medicine cabinets through centralized procurement [1][2] - The drug procurement policy has effectively reduced prices by squeezing out unreasonable price margins, providing tangible benefits for the public's medical needs. However, ensuring the quality of procured drugs is crucial for them to serve as a "guardian" of public health [1] - The latest procurement emphasizes strict quality requirements throughout the process, focusing on mature "old drugs" that have been in clinical use for many years, while excluding high-risk drugs from the procurement [1] - The procurement rules have introduced stringent quality thresholds, requiring bidding companies to have relevant production experience and for the drugs to pass regulatory compliance checks. Only companies with stable quality and practical production experience can participate in the bidding [1] Industry Regulations - Successful bidding does not guarantee protection for pharmaceutical companies, as regulatory authorities will conduct comprehensive supervision of selected drugs. If quality issues arise during subsequent inspections, the company will lose its selection qualification and be placed on a violation list, prohibiting participation in future procurements for a specified period [2] - Continuous reinforcement of quality supervision throughout the entire lifecycle of drug production, distribution, and use is essential. Pharmaceutical companies must take responsibility for drug quality and safety as a lifeline [2] - A combination of strict process management and dynamic monitoring is necessary to maintain the quality of drugs, ensuring that the benefits of the procurement policy truly reach the public [2]

Core Viewpoint - The article emphasizes the importance of ensuring the quality of drugs in the national centralized procurement system, which aims to provide affordable and reliable medications to the public while maintaining stringent quality standards [1][2]. Group 1: Drug Procurement Success - The 11th batch of national centralized drug procurement successfully included 55 types of drugs, contributing to a total of 490 quality and affordable essential and life-saving drugs available to the public over the past seven years [1]. - The centralized procurement policy has effectively reduced drug prices by leveraging volume to negotiate better rates, benefiting patients in terms of medical costs [1]. Group 2: Quality Assurance Measures - Ensuring drug quality is critical; the procurement process has tightened quality controls, focusing on well-established "old drugs" with a history of clinical use, while excluding high-risk drugs from the current procurement [1]. - New procurement rules set strict quality thresholds, requiring bidding companies to have relevant production experience and compliance with drug production quality management standards [1]. Group 3: Regulatory Oversight - The regulatory authorities will conduct comprehensive supervision of selected drugs, with the power to revoke procurement qualifications if quality issues arise during post-selection inspections [2]. - Continuous quality monitoring throughout the drug production, distribution, and usage processes is essential, alongside the responsibility of pharmaceutical companies to prioritize drug safety [2].

Core Points - The recent 11th batch of national centralized drug procurement successfully awarded contracts for 55 drugs, contributing to a total of 490 quality and affordable essential and life-saving drugs entering the market over the past seven years [1] - The drug procurement policy aims to reduce prices through volume-based purchasing while ensuring drug quality remains a priority, emphasizing the need for stringent quality control throughout the procurement process [1][2] - New procurement rules require participating companies to have relevant production experience and compliance with quality management standards, ensuring that only qualified manufacturers can bid [1] Group 1 - The centralized drug procurement has successfully introduced 490 essential drugs into the market, benefiting public health [1] - The procurement process focuses on quality assurance, tightening controls on drug quality and ensuring that only established, low-risk drugs are included [1][2] - Strict quality thresholds have been established for bidding companies, requiring them to demonstrate production experience and compliance with regulatory standards [1] Group 2 - Continuous monitoring and regulation of selected drugs will be enforced, with penalties for companies that fail to maintain quality standards post-selection [2] - The emphasis on quality control throughout the drug lifecycle is crucial for ensuring public trust and safety in the procurement process [2] - A dual approach of strict process management and dynamic monitoring is necessary to uphold drug quality and realize the benefits of the procurement policy [2]

回溯政策源头，2024年5月，国家医保局办公室发布《关于加强区域协同做好2024年医药集中采购提质 扩面的通知》，首次在国家层面明确提出"各省份要鼓励村卫生室、民营医疗机构和零售药店参加集 采"，为集采药品向基层终端延伸奠定基础。 彼时江西省率先响应，出台《江西省集采药品"三进"行动实施方案（征求意见稿）》，明确在全省范围 推进集采药品进"零售药店、民营医疗机构、村卫生室（含社区卫生服务中心/站）"，并首次将这一举 措凝练为行业通行的"三进"。 此后浙江省、广东省、大同市等多省市接连发布方案，纷纷加入推进集采药品进基层医疗机构、进民营 医疗机构、进零售药店的行列，推动政策落地范围持续扩大。 从成效来看，北京中医药大学卫生健康法学教授、博士生导师邓勇向21世纪经济报道记者表示，一方 面，提升了药品可及性与覆盖率。以江西为例，截至2025年9月30日，全省医保定点基层医疗机构、民 营医疗机构、零售药店中自愿申请参加的覆盖率达73.6%，"三进"品种的覆盖产品数、采购量和采购金 额都有显著增长。另一方面，降低了患者用药负担。集采药品价格通常较低，进入第三终端市场后，拉 低了市场整体的药品价格水平，使患者能以更实惠的 ...